[Current treatment for multiple sclerosis]

Several drugs are now available to treat multiple sclerosis. MS treatment has included immunomodulatory agents for 15 years; monoclonal antibody therapies have recently been added. IFN beta and Glatiramer acetate are effective in reducing relapses and lesions visible on magnetic resonance imaging (MRI) in patients with MS. Natalizumab, a monoclonal antibody, reduces the short-term risk of increasing disability and the rate of clinical relapse in patients with relapsing MS. Clinical trials are currently underway to assess the efficacy of other monoclonal antibodies and immunosuppressors. In the future, remyelinating and neuroprotective approach offers new perpectives.